PrecisemAb Biotech
Taipei, Taiwan· Est.
A Taiwan biotech delivering safer, tumor‑selective antibodies via a protease‑activated lock technology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A Taiwan biotech delivering safer, tumor‑selective antibodies via a protease‑activated lock technology.
OncologyImmunology
Technology Platform
Universal Antibody Lock™ (U‑Lock) masks antibody binding with a protease‑cleavable peptide, enabling activation only in disease‑specific microenvironments to improve selectivity and safety.
Opportunities
The lock technology can be licensed to existing antibody programs, enabling faster market entry and partnerships with large pharma seeking safer biologics.
Risk Factors
Translating conditional activation from animal models to humans may face unforeseen immunogenicity or protease variability, and substantial funding is needed for clinical development.
Competitive Landscape
Competitors include traditional antibody developers and emerging conditional‑activation platforms; Precisemab differentiates itself with a universal lock system applicable across multiple antibody formats.